The following are the top rated Healthcare stocks according to Validea's Patient Investor model based on the published strategy of Warren Buffett. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.
GENMAB A/S - ADR (GMAB) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Warren Buffett is 99% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| EARNINGS PREDICTABILITY: | PASS |
| DEBT SERVICE: | PASS |
| RETURN ON EQUITY: | PASS |
| RETURN ON TOTAL CAPITAL: | PASS |
| FREE CASH FLOW: | PASS |
| USE OF RETAINED EARNINGS: | PASS |
| SHARE REPURCHASE: | NEUTRAL |
| INITIAL RATE OF RETURN: | PASS |
| EXPECTED RETURN: | PASS |
Detailed Analysis of GENMAB A/S - ADR
MEDIFAST INC (MED) is a small-cap value stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Warren Buffett is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Medifast, Inc. sells a variety of weight loss, weight management and healthy living products all based on its own formulas under the OPTAVIA, Optimal Health by Take Shape for Life, and Flavors of Home brands. The Company's product line includes approximately 95 consumable options, including, but not limited to, bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes and soups. The Company's nutritional products are formulated with ingredients. The processing, formulation, packaging, labeling and advertising of the Company's products are subject to regulation by one or more federal agencies, including the Food and Drug Administration (FDA), the Federal Trade Commission (the FTC), the Consumer Product Safety Commission, the United States Department of Agriculture and the United States Environmental Protection Agency.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| EARNINGS PREDICTABILITY: | PASS |
| DEBT SERVICE: | PASS |
| RETURN ON EQUITY: | PASS |
| RETURN ON TOTAL CAPITAL: | PASS |
| FREE CASH FLOW: | FAIL |
| USE OF RETAINED EARNINGS: | PASS |
| SHARE REPURCHASE: | PASS |
| INITIAL RATE OF RETURN: | PASS |
| EXPECTED RETURN: | PASS |
Detailed Analysis of MEDIFAST INC
CHEMED CORPORATION (CHE) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Warren Buffett is 86% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Chemed Corporation is focused on purchasing, operating, and divests subsidiaries in diverse business activities. The Company's segments include VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The VITAS segment provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. The Company's VITAS business is operated in the state of Florida. The Roto-Rooter segment provides plumbing, drain cleaning, excavation, water restoration and other related services to residential and commercial customers. The Company services are provided through a network of Company-owned branches, independent contractors, and franchisees. The Company operates through its two wholly owned subsidiaries VITAS Healthcare Corporation and Roto-Rooter Group, Inc.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| EARNINGS PREDICTABILITY: | PASS |
| DEBT SERVICE: | PASS |
| RETURN ON EQUITY: | PASS |
| RETURN ON TOTAL CAPITAL: | PASS |
| FREE CASH FLOW: | PASS |
| USE OF RETAINED EARNINGS: | PASS |
| SHARE REPURCHASE: | PASS |
| INITIAL RATE OF RETURN: | PASS |
| EXPECTED RETURN: | PASS |
Detailed Analysis of CHEMED CORPORATION
CORVEL CORPORATION (CRVL) is a mid-cap growth stock in the Healthcare Facilities industry. The rating according to our strategy based on Warren Buffett is 86% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: CorVel Corporation is engaged in applying technology, including artificial intelligence, machine learning and natural language processing designed to address the management of care and the related health-care costs. It provides a range of services, including claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and Medicare services. It partners with employers, third party administrators (TPAs), insurance companies, and government agencies to assist its customers in managing the medical costs of workers compensation, group health and auto insurance, and in monitoring the quality of care provided to claimants. Its network solutions services include professional nurse review, expert fee negotiations, specialty networks, preferred provider organization management, medical bill repricing, automated adjudication, and electronic reimbursement. Its bill review services include Coding review and re-bundling.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| EARNINGS PREDICTABILITY: | PASS |
| DEBT SERVICE: | PASS |
| RETURN ON EQUITY: | PASS |
| RETURN ON TOTAL CAPITAL: | PASS |
| FREE CASH FLOW: | PASS |
| USE OF RETAINED EARNINGS: | PASS |
| SHARE REPURCHASE: | PASS |
| INITIAL RATE OF RETURN: | PASS |
| EXPECTED RETURN: | PASS |
Detailed Analysis of CORVEL CORPORATION
RESMED INC. (RMD) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Warren Buffett is 86% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep-disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other chronic diseases. The Company operates through two segments: Sleep and Respiratory Care segment, and the Software-as-a-Service (SaaS) segment. Sleep apnea includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital health applications, along with its devices, are designed to provide connected care to improve patient outcomes. The Company's portfolio of products includes ventilation devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| EARNINGS PREDICTABILITY: | PASS |
| DEBT SERVICE: | PASS |
| RETURN ON EQUITY: | PASS |
| RETURN ON TOTAL CAPITAL: | PASS |
| FREE CASH FLOW: | FAIL |
| USE OF RETAINED EARNINGS: | PASS |
| SHARE REPURCHASE: | PASS |
| INITIAL RATE OF RETURN: | PASS |
| EXPECTED RETURN: | PASS |
Detailed Analysis of RESMED INC.
More details on Validea's Warren Buffett strategy
About Warren Buffett: Warren Buffett is considered by many to be the greatest investor of all time. As the chairman of Berkshire Hathaway, Buffett has consistently outperformed the S&P 500 for decades, and in the process has become one of the world's richest men. (Forbes puts his net worth at $37 billion.) Despite his fortune, Buffett is known for living a modest lifestyle, by billionaire standards. His primary residence remains the gray stucco Nebraska home he purchased for $31,500 nearly 50 years ago, according to Forbes, and his folksy Midwestern manner and penchant for simple pleasures -- a cherry Coke, a good burger, and a good book are all near the top of the list -- have been well-documented.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
